Skip to content

Source filing unavailable

Q3 2012 · —
Revenue$210.08M+3.9% vs Q3 2011−0.0% vs Q2 2012
Net Income$13.21M+17.5% vs Q3 2011+55.2% vs Q2 2012
EPS Diluted$0.46+17.9% vs Q3 2011+53.3% vs Q2 2012
Gross Profit$130,536,000+5.7%
Operating Income$19,736,000+7.9%
Operating Cash Flowderived$27,909,000+17.3%
Free Cash Flowderived$8,192,000−29.1%
Margins · derived
Gross margin62.1%+1.0 pt vs Q3 2011
Operating margin9.4%+0.3 pt vs Q3 2011
Net margin6.3%+0.7 pt vs Q3 2011

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2012Q3 2011Q3 2010Q3 2009
Revenue$210.08M$202.19M$186.64M$172.29M
Net Income$13.21M$11.24M$16.48M$14.43M
EPS Diluted$0.46$0.39$0.55$0.49

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR